Real World MAIA UK Outcomes - Observational Myeloma Trial, DRd Therapy
Summary
The NIH registered observational study NCT07532473 on ClinicalTrials.gov to assess real-world use and clinical outcomes of triplet therapy daratumumab, lenalidomide, and dexamethasone (DRd) in transplant-ineligible patients with untreated myeloma in the United Kingdom. The observational study will describe treatment patterns and associated clinical outcomes outside of clinical trial settings.
What changed
A new observational study (NCT07532473) titled 'Real World MAIA UK Outcomes' was registered on ClinicalTrials.gov by the NIH. The study will evaluate real-world use and clinical outcomes of triplet therapy with daratumumab, lenalidomide, and dexamethasone (DRd) in transplant-ineligible (TIE) patients with untreated myeloma in the United Kingdom.
Affected parties include UK oncology and hematology healthcare providers and clinical investigators conducting or referring patients for myeloma treatment, as well as pharmaceutical manufacturers of the drug components. This registry entry is informational and does not impose compliance obligations but provides transparency on ongoing real-world evidence collection for this indication.
Archived snapshot
Apr 16, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
REal World MAIA UK OutcomEs
Observational NCT07532473 Kind: OBSERVATIONAL Apr 16, 2026
Abstract
This study will describe the use of triplet therapy with daratumumab, lenalidomide and dexamethasone (DRd) in the treatment of for transplant ineligible (TIE) untreated myeloma outside of clinical trials and assess the associated clinical outcomes.
Conditions: Myeloma
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.